Abstract: A mimic of an anti-angiogenic peptide is combined with a self-assembling peptide hydrogel to provide improved treatment for pathological neovascularization management. Pathological neovascularization may cause or worsen intraocular posterior segment diseases, such as diabetic retinopathy (DR) and wet age-related macular degeneration (wet AMD). The attachment of a therapeutic anti-angiogenic motif to a fibrillizing peptide backbone that undergoes nanofibrous self-assembly into an injectable hydrogel was found beneficial for the treatment of aberrant neovascularization. The peptide persists for extended periods in a target site for prolonging the therapeutic timeframe. This injectable hydrogel therapy may unlock potential clinical routes for treating many neovascular diseases.